Dr. Jordan has over 2 decades of experience developing, validating and implementing molecular-based tests for infectious disease diagnostics. Since moving to GWU School of Public Health she has continued to receive funding from NIH (NIH NIAID R01; bacterial sepsis, Jordan-PI) and is currently PI of an NIH NCI R01 where she is looking to identify companion diagnostics to the anal Pap test that would improve the specificity for predicting high-grade lesion (AIN2+) in HIV-infected men who have sex with men. The goal is to help determine when the high resolution anoscopy procedure is warranted, but to also help prevent unnecessary biopsies (high resolution anoscopy) when not needed.
Her research laboratory is certified by the Immunology Quality Assurance Center at Duke University enabling her laboratory to do sample processing for the GWU CTU (Magnus-PI), which includes HPTN, HVTN and ACTG-supported studies carried out at both GWU and WWH. She has also been the site PI for several multi-site clinical trials evaluating HIV-1 Qualitative and Viral Load Assays (Cepheid) that received CE-IVD and FDA clearance.
She is currently the Director of the DC-CFAR Sequencing Core that support sequencing for any DC CFAR member whose research requires this cutting edge technology. 2021 brought with it the opportunity to help support NGS efforts for SARS-CoV-2 both for the DC DFS/PHL and for the GWU community.